New York-based C2i Genomics, a company developing a breakthrough tumor pattern recognition approach for liquid biopsy, raised $12 million in its series A financing. The financing was led by Casdin Capital and joined by additional new investors including Nfx Capital, The Mark Foundation for Cancer Research and other investors. Proceeds from the financing will be used to fund the development and clinical validation of C2i Genomics’ personalized, real-time solution for monitoring recurrence and treatment response for various types of solid cancers.

South San Francisco-based Caredx Inc., a precision medicine company focused on the development of clinically differentiated health care solutions for transplant patients and caregivers, said it plans to offer and sell up to $100 million of shares of its common stock in an underwritten public offering. Caredx also expects to grant the underwriters of the offering a 30-day option to purchase up to an additional $15 million of shares of its common stock offered in the public offering on the same terms and conditions. All of the shares will be offered and sold by the company. It intends to use the net proceeds from this offering for working capital and general corporate purposes. Goldman Sachs & Co. LLC and Jefferies LLC are acting as joint book-running managers for the offering. BTIG, LLC and Craig-Hallum Capital Group are acting as co-managers for the offering.

Mountain View, Calif.-based DNAnexus Inc., a cloud-based SaaS company serving the global life science community, reported the closing of a $100 million financing round. The financing was led by Perceptive Advisors and Northpond Ventures, joining existing investors GV, Foresite Capital, TPG Capital, and First Round Capital, and first-time equity investor Regeneron Pharmaceuticals. These funds will advance the company’s growth globally, enabling DNAnexus to further serve health care and life science organizations. The DNAnexus Platform accelerates digital transformation by simplifying complex data analysis, clinical data management, and insights.

Boston-based Patientping Inc., a care collaboration and e-notifications platform, has raised $60 million in series C funding to fuel expansion to new geographies and extend capabilities. The investment round, co-led by Andreessen Horowitz, F-Prime Capital, GV (formerly Google Ventures), and Transformation Capital, with additional participation from existing investors, brings PatientPing's total funding to more than $100 million.

No Comments